Meitheal Pharmaceuticals Announces FDA Approval of GarzulysTM (insulin aspart-fsan) Injection

Source Summary

CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company headquartered in Chicago and focused on the development and commercialization of generic injectable medicines, biologics, fertility products and branded medicines, today announced that the U.S. Food and Drug Administration (“FDA”) has approved GarzulysTM (insulin aspart-fsan) injection, a biosimilar to NovoLog® (insulin aspart). Emerge Bioscience Pte. Ltd. (“Emerge”) is the holder